Ignite Creation Date:
2025-12-25 @ 4:14 AM
Ignite Modification Date:
2026-04-23 @ 10:20 PM
Study NCT ID:
NCT06525220
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2024-07-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Sponsor:
Merus N.V.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MCLA-158-CL03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None